ex10-15.htm


    
      
        

        EXHIBIT
10.15

         

      

    

     

    FORM
OF SERIES B SECURITIES PURCHASE AGREEMENT

     

              THIS
SECURITIES
PURCHASE AGREEMENT (this “Agreement”)
is made as of the ____ day of March, 2009, by and among HEALTH
DISCOVERY CORPORATION, a Georgia corporation (the “Company”),
and the investors listed on Schedule A hereto (the “Purchasers”).

     

              WHEREAS,
the Company and the Purchasers are executing and delivering this Agreement in
reliance upon the exemption from securities registration afforded by Rule 506
under Regulation D as promulgated by the United States Securities and Exchange
Commission (the “Commission”)
under Section 4(2) of the Securities Act of 1933, as amended (the “Securities
Act”);

     

              WHEREAS,
subject to the terms and conditions set forth in this Agreement, the Company
desires to issue and sell to the Purchasers, and the Purchasers desires to
purchase from the Company, shares
(the “Shares”)
of Series B Preferred Stock of the Company, no par value (the “Preferred
Stock”);

     

              WHEREAS,
this Agreement and the sale of the Shares to the Purchasers is a part of
a private offering (the “Offering”)
with an aggregate minimum gross proceeds of at least $100,000.00 (the “Minimum
Amount”).

     

              NOW,
THEREFORE, in consideration of the promises and mutual covenants and
agreements herein, the Company and the Purchasers hereby agree as
follows:

     

    ARTICLE
I.

    PURCHASE
AND SALE

     

              1.1          Purchase
and Sale. Subject to the terms and conditions set forth herein, the
Company shall issue and sell to each Purchaser, and each Purchaser, severally
and not jointly, agrees to purchase from the Company, at the Closing (as defined
below) that number of Shares set forth opposite the Purchaser’s name on Schedule
A for the amount set forth on such Schedule (the “Purchase
Price”).

     

              1.2          Closing.

     

                             a.          The
Closing. The initial closing (the “Initial
Closing” or the “Closing”)
of the purchase and sale of the Shares shall take place on March ___, 2009, or
such other time as the Company and the Purchasers shall otherwise agree (the
“Closing
Date”).

     

                             b.          Purchasers’
Deliveries at Closing. At each Closing, each Purchaser must deliver to
the Company the following:

     

                                          (i)          a
copy of this Agreement, duly executed by such Purchaser,

     

                                          (ii)         a
completed Purchaser Questionnaire in for form of Exhibit A, attached hereto;
and

     

                                          (iii)        the
Purchase Price to be paid by wire transfer, bank check or money
order.

     

                             c.          Company
Deliveries at Closing. At the Closing, the Company shall deliver to each
Purchaser (at each Purchaser’s address listed on the signature page of this
Agreement):


    
      
         


      

      
         


        
          

        

      

      
         


      

    

     

                                              (i)          one
copy of this Agreement, duly executed by the Company, and

     

                                          (ii)         a
certificate evidencing the Shares registered in the books and records of the
Company in the name of each Purchaser or the Purchaser’s nominee.

     

              1.3          Sale
of Additional Shares.

     

                             a.          After
the Initial Closing, the Company may sell, on the same terms and conditions as
those contained in this Agreement (subject to equitable and proportional
adjustment in the event of any stock dividend, stock split, reverse stock
dividend or reverse stock split, or any capital reorganization or
recapitalization or similar event affecting the common stock of the Company,
which becomes effective after the date of this Agreement and on or before the
Closing Date), additional shares of Series B Preferred Stock (the “Additional
Shares”) to one or more purchasers (the “Additional
Purchasers”) in one or more subsequent closings provided that (i) such
subsequent sales, together with the sales to the Purchasers, do not result in
gross proceeds to the Company of greater than $1,100,000 (the “Maximum
Amount”), (ii) such subsequent sales are consummated on or prior to
December 31, 2009, and (iii) each Additional Purchaser shall become a party to
this Agreement, as defined below, by executing and delivering a counterpart
signature page to this Agreement. Schedule
A to this Agreement shall be updated to reflect the number of Additional
Shares purchased at each such Closing and the parties purchasing such Additional
Shares.

     

                             b.          Prior
to the Initial Closing, Additional Purchasers may, with the written consent of
the Company, become a party to this Agreement by executing and delivering a
counterpart signature page to this Agreement, in which event (i) such Additional
Purchasers will purchase their Additional Shares at the Initial Closing and (ii)
Schedule
A to this Agreement will be updated to reflect the number of Additional
Shares purchased and the parties purchasing such Additional Shares.
Notwithstanding the foregoing, any Additional Purchasers may not become a party
to this Agreement to the extent his, her or its purchase of Additional Shares at
the Initial Closing would result in the aggregate Purchase Price for total sales
of Shares to all Purchasers in the Offering in an amount exceeding the Maximum
Amount.

     

    ARTICLE
II.

    REPRESENTATIONS
AND WARRANTIES

     

              2.1          Representations
and Warranties of the Company. The Company represents and warrants to the
Purchasers that, to its knowledge, the statements contained in this Section 2.1
are true, correct and complete, in all material respects, as of the date of this
Agreement, and will be true correct and complete, in all material respects, as
of the Closing Date.

     

                             a.          Organization
and Qualification. The Company is duly incorporated, validly existing and
in good standing under the laws of the State of Georgia, with the requisite
corporate power and authority to carry on its business as currently conducted.
The Company is duly qualified as a foreign corporation to do business and is in
good standing as a foreign corporation in each jurisdiction in which the nature
of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as
the case may be, would not, individually or in the aggregate, (x) adversely
affect the legality, validity or enforceability of this Agreement or any of the
transactions contemplated hereby, (y) have or result in a material adverse
effect on the condition (financial or otherwise), business, operations, results
of operations, assets, capitalization, financial condition, licenses, permits,
rights or privileges (whether contractual or otherwise) or prospects of the
Company, taken as a whole, or (z) impair the Company’s ability to perform fully
on a timely basis its obligations hereunder (an effect caused by or change
resulting from any event or circumstance described in clause (x), (y) or (z),
being a “Material
Adverse Effect”). The Company has made available to the Purchasers true
and correct copies of the Company’s Articles of Incorporation, as in effect on
the date of this Agreement (the “Articles
of Incorporation”), and the Company’s Bylaws, as in effect on the date of
this Agreement (the “Bylaws”).


    
      
         


      

      
        2

        
          

        

      

      
         


      

    

     

                             b.          Authorization;
Enforcement. The Company has the requisite corporate power and authority
to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder. The execution and delivery
of this Agreement by the Company and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action
by the Company. This Agreement has been duly executed by the Company and when
delivered in accordance with the terms hereof will constitute the valid and
binding obligation of the Company enforceable against the Company in accordance
with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally the enforcement of, creditors’ rights and
remedies or by other equitable principles of general application and except that
rights to indemnification and contribution may be limited by federal or state
securities laws or public policy relating thereto.

     

                             c.          Capitalization.
As of the date of this Agreement, the authorized capital stock of the Company
consists of 300,000,000 shares of Common Stock, of which 169,522,590 shares are
issued and outstanding, 30,000,000 shares of preferred stock, of which 7,437,184
shares are issued and outstanding and designated “Series A Preferred Stock,” and
13,750,000 shares will be designated “Series B Preferred Stock,” and options and
warrants to acquire 126,277,644 shares of Common Stock have been granted and
remain outstanding. Except as described in Section 2.1(c) of the attached
Disclosure Schedule, no Person (as hereinafter defined) has any right of first
refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by this Agreement. The issuance and
sale of the Shares will not obligate the Company to issue shares of Common Stock
or other securities to any Person (other than the Purchasers) and will not
result in a right of any holder of Company securities to adjust the exercise,
exchange, conversion or reset price under such securities.

     

                             d.          Authorization
and Validity; Issuance of Shares. The Shares are duly authorized and,
when issued and paid for in accordance with this Agreement, will be validly
issued, fully paid and non-assessable, free and clear of all liens.

     

                             e.          No
Conflicts. The execution, delivery and performance of this Agreement by
the Company and the consummation by the Company of the transactions contemplated
hereby do not and will not (i) conflict with or violate any provision of the
Articles of Incorporation, Bylaws or other organizational documents of the
Company, (ii) subject
to obtaining the consents referred to in Section 2.1(f), conflict with, or
constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company is a party or by which any
property or asset of the Company is bound or affected, or (iii) result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which the Company is
subject or by which any material property or asset of the Company is
bound.

     

                             f.          Consents
and Approvals. The Company is not required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other
governmental authority, regulatory or self regulatory agency, or other Person in
connection with the execution, delivery and performance by the Company of this
Agreement, other than (i) any required application(s) or any letter(s)
acceptable to the Over-the-Counter Bulletin Board (“OTCBB”),
and (ii) any filings, notices or registrations under applicable federal or state
securities laws (the “Required
Approvals”), except where failure to do so has not resulted or would not
reasonably result, individually, or in the aggregate, in a Material Adverse
Effect. “Person”
means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity
of any kind.


    
      
         


      

      
        3

        
          

        

      

      
         


      

    

     

                             g.          Litigation;
Proceedings. Except as specifically set forth on in the SEC Documents or
Section 2.1(g) of the attached Disclosure Schedule there is no action, suit,
notice of violation, proceeding or investigation pending or threatened against
or affecting the Company or any of its subsidiaries or any of their respective
properties before or by any court, governmental or administrative agency or
regulatory authority (collectively, an “Action”)
which (i) adversely affects or challenges the legality, validity or
enforceability of any of this Agreement, or (ii) would reasonably be expected
to, individually or in the aggregate, have a Material Adverse Effect. There has
not been, and there is not pending or contemplated, any investigation by the
Commission involving the Company or any current or former director that was a
director of the Company at any time during the last three years or officer of
the Company. The Commission has not issued any stop order or other order
suspending the effectiveness of any registration statement filed by the Company
or any subsidiary under the Exchange Act of 1934, as amended (the “Exchange
Act”) or the Securities Act.

     

                             h.          No
Default or Violation. The Company (i) is not in default under or in
violation of any indenture, loan or other credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its
properties is bound and which is required to be included as an exhibit to any
SEC Document, (ii) is not in violation of any order of any court, arbitrator or
governmental body applicable to it, (iii) is not in violation of any
statute, rule or regulation of any governmental authority to which it is
subject, (iv) is not in default under or in violation of its Articles of
Incorporation, Bylaws or other organizational documents, respectively in the
case of (i), (ii) and (iii), except where such violations have not resulted or
would not reasonably result, individually or in the aggregate, in a Material
Adverse Effect.

     

                             i.          SEC
Documents; Financial Statements. Since January 1, 2007, the Company has
filed all reports, schedules, forms, statements and other documents required to
be filed by it, with the Commission, pursuant to Section 13, 14 or 15(d) of the
Exchange Act (collectively referred to herein as the “SEC
Documents”). As of their respective dates, the SEC Documents complied in
all material respects with the requirements of the Securities Act and the
Exchange Act and the rules and regulations of the Commission promulgated
thereunder applicable to such SEC Document. Except to the extent that
information contained in any SEC Document filed and publicly available prior to
the date of this Agreement has been revised or superseded by a later filed SEC
Document, which later filed SEC Document was filed prior to the date of this
Agreement, none of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents comply as to form in all
material respects with applicable accounting requirements and the published
rules and regulations of the Commission with respect thereto as in effect at the
time of filing. Such financial statements fairly present in all material
respects the financial position of the Company as of and for the dates thereof
and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, year-end audit
adjustments.


    
      
         


      

      
        4

        
          

        

      

      
         


      

    

     

                             j.          Material
Changes. Since the date of the latest audited financial statements
included within the SEC Documents, except as specifically disclosed in the SEC
Documents, (i) there has been no event, occurrence or development that has had a
Material Adverse Effect, (ii) the Company has not incurred any liabilities other
than (A) trade payables and accrued expenses incurred in the ordinary course of
business consistent with past practice, and (B) liabilities not required to be
reflected in the Company’s financial statements pursuant to GAAP or required to
be disclosed in filings made with the Commission, (iii) the Company has not
altered its method of accounting or the identity of its auditors, and (iv) the
Company has not declared or made any dividend or distribution of cash or other
property to its shareholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock.

     

                             k.          Listing
and Maintenance Requirements. The Company has not, in the two years
preceding the date of this Agreement, received notice from the OTCBB or any
other exchange or market on which the Common Stock is or has been listed or
quoted to the effect that the Company is not in compliance with the listing or
maintenance requirements of such exchange or market. The Company is, and has no
reason to believe that it will not in the foreseeable future continue to be, in
compliance with all such listing and maintenance requirements of the OTCBB. The
issuance and sale of the Shares hereunder does not contravene the rules and
regulations of the OTCBB and approval of the shareholders of the Company is not
required for the Company to issue and deliver to the Purchasers the number of
Shares contemplated by this Agreement.

     

                             l.          Broker’s
Fees. The Purchasers shall have no obligation with respect to any fees or
with respect to any claims made by or on behalf of other Persons for fees of any
broker, finder or other intermediary retained by the Company that may be due in
connection with the transactions contemplated by this Agreement.

     

              2.2       Representations,
Warranties and Covenants of the Purchasers.

     

                             a.          Purchasers
Status. Purchasers represent and warrant to, and covenants with, the
Company that: (i) each Purchaser is an “accredited investor” as defined in
Regulation D under the Securities Act, and each Purchaser is also knowledgeable,
sophisticated and experienced in making, and is qualified to evaluate the risks
and merits and make decisions with respect to investments in securities
presenting an investment decision like that involved in the purchase of the
Shares, including investments in securities issued by the Company and
investments in comparable companies, and has requested, received, reviewed and
considered all information it deemed relevant in making an informed decision to
purchase the Shares and is able to bear the risks of this investment;
(ii) each Purchaser is acquiring the Shares in the ordinary course of its
business and for its own account for investment only and not with a view to, or
for resale in connection with, any distribution thereof within the meaning of
the Securities Act; (iii) each Purchaser will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to
buy, purchase or otherwise acquire or take a pledge of) any of the Shares except
in compliance with the Securities Act, applicable state securities laws and the
respective rules and regulations promulgated thereunder; (iv) each Purchaser
has, in connection with its decision to purchase the Shares, relied only upon
the SEC Documents and the representations and warranties of the Company
contained herein, (v) each Purchaser has answered all questions on the Investor
Questionnaire and the answers thereto are true, correct and complete in all
material respects as of the date hereof and will be true, complete and correct
in all material respects as of the Closing Date; and (vi) each Purchaser will
notify the Company immediately of any material change in any of such information
until the Closing. Purchasers understands that its acquisition of the Shares has
not been registered under the Securities Act or registered or qualified under
any state securities law in reliance on specific exemptions therefrom, which
exemptions may depend upon, among other things, the bona fide nature of the
Purchasers’ investment intent as expressed herein, and the Company is not
required and never intends to so register the Shares.


    
      
         


      

      
        5

        
          

        

      

      
         


      

    

     

                             b.          Resale
Restrictions. Each Purchaser hereby covenants with the Company not to
make any sale of the Shares without complying with the provisions of this
Agreement and without satisfying all requirement of an applicable exemption
under the Securities Act for such sale. Each Purchaser acknowledges that the
Shares will be imprinted with the following legend that prohibits their transfer
except in accordance therewith:

    
      	 
      	 
      
	 
      	
              THE
      SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES
      AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION IN RELIANCE
      UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS
      AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR
      SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
      SECURITIES ACT OR AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
      SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
      ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
      OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
      WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
  COMPANY.

            


    

     

                             c.          Short
Position. Each Purchaser hereby covenants with the Company not to use any
of the Shares acquired pursuant to this Agreement to cover any short position in
the Common Stock of the Company if doing so would be in violation of applicable
securities laws.

     

                             d.          No
Advice. Each Purchaser understands that nothing in the SEC Documents,
this Agreement or any other materials presented to the Purchasers in connection
with the purchase and sale of the Shares constitutes legal, tax or investment
advice. Each Purchaser has consulted such legal, tax and investment advisors as
it, in its sole discretion, has deemed necessary or appropriate in connection
with its purchase of the Shares.

     

                             e.          Organization;
Authority. Each Purchaser is either an individual residing in the state
as set forth on the signature page of this Agreement, or a corporation, limited
liability company or limited partnership duly formed, validly existing and in
good standing under the laws of the jurisdiction of its incorporation or
formation with the requisite power and authority to enter into and to consummate
the transactions contemplated by this Agreement and to carry out the obligations
hereunder. The purchase by Purchasers of the Shares hereunder has been duly
authorized by all necessary action on the part of the Purchasers. This Agreement
has been duly executed and delivered by each Purchaser and constitutes the valid
and legally binding obligation of each Purchaser, enforceable against each
Purchaser in accordance with its terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general
applicability relating to or affecting creditors’ rights generally and to
general principles of equity and except that rights to indemnification and
contribution may be limited by federal or state securities laws or public policy
relating thereto.

     

                             f.          Risk.
Each Purchaser has carefully reviewed and understands the risks of, and other
considerations relating to, the purchase of the Shares, and an investment in the
Company. Each Purchaser has adequate means of providing for its current needs
and possible future contingencies, and each Purchaser has no need, and
anticipates no need in the foreseeable future, to sell or otherwise transfer the
Shares. Each Purchaser is able to bear the economic risks of this investment
and, consequently, without limiting the generality of the foregoing, each
Purchaser is able to hold the Shares for an indefinite period of time and has
sufficient net worth to sustain a loss of its entire investment in the Company
if such loss should occur. Each Purchaser understands that the purchase of the
Shares is a highly speculative investment, which involves a high degree of risk
of loss of each Purchaser’s entire investment therein.


    
      
         


      

      
        6

        
          

        

      

      
         


      

    

     

                             g.          Reliance.
Each Purchaser understands and acknowledges that (i) the Shares are being
offered and sold to the Purchasers without registration under the Securities Act
in a private placement that is exempt from the registration provisions of the
Securities Act under Section 4(2) of the Securities Act or Regulation D
promulgated thereunder, and (ii) the availability of such exemption depends in
part on, and the Company will rely upon the accuracy and truthfulness of, the
representations set forth in this Section 2.2, including, without limitation,
the accredited investor status and the investment intent of the Purchasers, and
each Purchaser hereby consents to such reliance.

     

                             h.          Information.
Each Purchaser and its advisors, if any, have been furnished with all materials
relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Shares which have been requested by
Purchasers or its advisors. Each Purchaser and its advisors, if any, have been
afforded the opportunity to ask questions of the Company and receive answers
concerning the terms and conditions of the offering and obtain any additional
information, which the Company possesses or can acquire without unreasonable
effort or expense, that is necessary to verify the accuracy of any
representations or information set forth in any such material. Representatives
of the Company have adequately answered all inquiries that the Purchasers have
made of them concerning the Company or any other matters relating to the
operation of the Company and sale of the Shares.

     

                             i.          Taxes.
Each Purchaser is aware that the Company and its representatives assume no
responsibility for the tax consequences to the Purchasers of any investment in
the Company.

     

                             j.          No
Representation or Promise. No one has ever represented or promised
expressly or by implication, any of the following: (i) the approximate or
exact length of time that Purchasers will be required to remain as owner of the
Shares, (ii) the amount or type of profit, or loss (including tax
write-offs and/or tax benefits) to be realized, if any, as a result of the
Purchasers’ investment, or (iii) that the past performance or experience of
the officers or directors of the Company or any affiliate, their associates,
agents, or employees or of any other person gives any assurance that the Company
will be a success.

     

                             k.          Offering
Literature; No Advertisement. No Purchaser has been furnished any
offering literature other than, and has relied only on the information contained
in, (i) the SEC Documents, and (ii) this Agreement, including the exhibits and
schedules thereto. No Purchaser is purchasing the Shares as a result of, or
subsequent to, any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or meeting in which
representatives of the Company were in attendance.

     

                             l.          Governmental
Review. Each Purchaser understands that no United States federal or state
agency or any other government or governmental agency has passed upon or made
any recommendation or endorsement of the Shares. 

     

    ARTICLE
III.

    CONDITIONS

     

              3.1        Closing.

     

                             a.          Conditions
Precedent to the Obligation of the Company to Sell the Shares. The
obligation of the Company to sell the Shares is subject to the satisfaction or
waiver by the Company, at or before the Closing Date, of each of the following
conditions:

     

                                          (i)          the
representations and warranties of the Purchasers in this Agreement shall be true
and correct in all material respects as of the date when made and as of the
Closing Date;


    
      
         


      

      
        7

        
          

        

      

      
         


      

    

     

                                          (ii)         the
Purchasers shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by this Agreement to be
performed, satisfied or complied with by the Purchasers at or before the Closing
Date; and

     

                                          (iii)        no
statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental
authority of competent jurisdiction which prohibits the consummation of any of
the transactions contemplated by this Agreement.

     

                             b.          Conditions
Precedent to the Obligation of the Purchasers to Purchase the Shares. The
obligation of the Purchasers hereunder to acquire and pay for the Shares at the
Closing is subject to the satisfaction or waiver by the Purchasers, at or before
the Closing Date, of each of the following conditions:

     

                                          (i)          the
representations and warranties of the Company set forth in this Agreement shall
be true and correct in all material respects as of the date when made and as of
the Closing Date;

     

                                          (ii)         the
Company shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by this Agreement to be
performed, satisfied or complied with by the Company at or before the Closing
Date;

     

                                          (iii)        no
statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental
authority of competent jurisdiction which prohibits the consummation of any of
the transactions contemplated by this Agreement;

     

                                            (iv)        all
Required Approvals shall have been obtained;

     

                                             (v)         delivery
of all items deliverable under Section 1.2(c);

     

                                           (vi)        no
Material Adverse Effect shall have occurred or been threatened (and no
condition, event or development shall have occurred or been threatened involving
a prospective Material Adverse Effect) in respect of the Company or any of its
subsidiaries between the date of this Agreement and the Closing Date;
and

     

                                           (vii)        the
sales to the Purchasers hereunder shall not result in gross cash proceeds to the
Company in excess of the Maximum Amount.

     

    ARTICLE
IV.

    INDEMNIFICATION
& CONFIDENTIALITY

     

              4.1          Indemnification.

     

                              a.          By
the Company. The Company will indemnify and hold Purchasers harmless from
any and all losses, liabilities, obligations, claims, contingencies, damages,
costs and expenses, including all judgments, amounts paid in settlements, court
costs and reasonable attorneys’ fees and costs of investigation that Purchasers
may suffer or incur as a result of or relating to any misrepresentation, breach
or inaccuracy, or any allegation by a third party that, if true, would
constitute a breach or inaccuracy, of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement; provided,
however, that any and all payments made or due to a Purchaser by the Company as
a result of the obligations of this Section 4.1 shall be limited to, and in no
case shall exceed, the Purchase Price paid by such Purchaser, as stated in
Section 1.1 herein.


    
      
         


      

      
        8

        
          

        

      

      
         


      

    

     

                             b.          By
the Purchasers. Purchasers will indemnify and hold the Company harmless
from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of
investigation that the Company may suffer or incur as a result of or relating to
any misrepresentation, breach or inaccuracy, or any allegation by a third party
that, if true, would constitute a breach or inaccuracy, of any of the
representations, warranties, covenants or agreements made by such Purchasers in
this Agreement; provided, however, that any and all payments, in the aggregate,
made or due by such Purchasers as a result of the obligations of this Section
4.1 shall be limited to, and in no case shall exceed, the amount of the Purchase
Price (but no credit shall be granted for such payment for any obligation of the
Purchasers pursuant to this Section 4.1) paid by such Purchaser, as stated in
Section 1.1 herein.

     

              4.2          Confidential
Information. Purchasers represents to the Company that, at all times
during the Company’s offering of the Shares, the Purchasers have maintained in
confidence and have not used except in connection with its purchase of the
Shares pursuant hereto, all non-public information regarding the Company
received by the Purchasers from the Company or its agents (“Confidential
Information”), and covenants that it will continue to maintain in confidence
such information until such information becomes generally publicly available
other than through a violation of this provision by the Purchasers or its
agents. If Purchasers are required to disclose any Confidential Information in
legal proceedings (such as by deposition, interrogatory, request for documents,
subpoena, civil investigation demand, filing with any governmental authority or
similar process) Purchasers may do so without violating this Agreement;
provided, however, that before making any use or disclosure in reliance on this
paragraph the Purchasers shall give the Company at least fifteen (15) days prior
written notice (or such shorter period as required by law) specifying the
circumstances giving rise thereto and will furnish only that portion of the
Confidential Information which is legally required and will exercise its best
efforts to obtain reliable assurance that confidential treatment will be
accorded any Confidential Information so furnished.

     

    ARTICLE
V.

    MISCELLANEOUS

     

              5.1           Entire
Agreement. This Agreement, together with the Schedules and Exhibits
hereto, contain the entire understanding of the parties with respect to the
subject matter hereof and supersedes all prior agreements and understandings,
oral or written, with respect to such matters.

     

    
      
         


      

      
        9

        
          

        

      

      
         


      

    

     

    
                5.2           Notices.
Whenever it is provided herein that any notice, demand, request, consent,
approval, declaration or other communication shall or may be given to any of the
parties by another, or whenever any of the parties desires to give another any
such communication with respect to this Agreement, each such notice, demand,
request, consent, approval, declaration or other communication shall be in
writing, and shall be delivered in person with receipt acknowledged or by
registered or certified mail, return receipt requested, postage prepaid, or by
telecopy and confirmed by telecopy answerback addressed as
follows:

    

     

    
      	 
      	 
      
	
              If
      to the Company:

            	
              With
      a Copy to:

            
	 
      	 
      
	
                Health
      Discovery Corporation

            	
              Bryan
      Cave LLP

            
	
                2
      East Bryan Street, Suite #601

            	
              1201
      W. Peachtree Street, N.E., 14th Floor

            
	
                Savannah,
      GA 31401

            	
              Atlanta,
      Georgia 30309

            
	
                Attn:
      Stephen D. Barnhill, M.D.

            	
              Attn:
      Todd Wade, Esq.

            
	
                Facsimile:
      (912) 443-1989

            	
              Facsimile:
      (404) 572-6999

            
	 
      	 
      
	
              If
      to the Purchasers:

            	 
      
	 
      	 
      
	
                To
      the addresses listed on the signature pages of this
    Agreement.

            	 
      


    

     

    or at
such other address as may be substituted by notice given as herein provided. The
giving of any notice required hereunder may be waived in writing by the party
entitled to receive such notice. Every notice, demand, request, consent,
approval, declaration or other communication hereunder shall be deemed to have
been duly given and effective on the earliest of (a) the date of transmission,
if such notice or communication is delivered via facsimile prior to 5:30 p.m.
(New York City time) on a business day, (b) the next business day after the date
of transmission, if such notice or communication is delivered via facsimile on a
day that is not a business day or later than 5:30 p.m. (New York City time) on
any business day, (c) the business day following the date of mailing, if sent by
a U.S. nationally recognized overnight courier service, or (d) upon actual
receipt by the party to whom such notice is required to be given. As used
herein, a “business
day” means any day except Saturday, Sunday or a day which is a federal
legal holiday or a day on which banking institutions in the State of New York
are authorized or required by law or other governmental action to
close.

     

              5.3          Amendments;
Waivers. No provision of this Agreement may be waived or amended except
in a written instrument signed, in the case of an amendment, by both the Company
and the Purchasers or, in the case of a waiver, by the party against whom
enforcement of any such waiver is sought. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to
be a continuing waiver in the future or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of either party
to exercise any right hereunder in any manner impair the exercise of any such
right accruing to it thereafter.

     

              5.4          Headings.
The headings herein are for convenience only, do not constitute a part of this
Agreement, and shall not be deemed to limit or affect any of the provisions
hereof.

     

              5.5          Successors
and Assigns; Assignability; No Third-Party Beneficiaries. Neither this
Agreement nor any right, remedy, obligation or liability arising hereunder, or
by reason hereof, shall be assignable by the Purchasers without the prior
written consent of the Company; provided, however, that each Purchaser may
assign any of its rights under this Agreement to any of its affiliates. If this
Agreement is assigned, all covenants contained herein shall bind and inure to
the benefit of the parties hereto and their respective successors and assigns.
This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person.


    
      
         


      

      
        10

        
          

        

      

      
         


      

    

     

              5.6          Governing
Law; Waiver of Jury Trial. All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by
and construed and enforced in accordance with the internal laws of the State of
Georgia, without regard to the principles of conflicts of law thereof. Each
party agrees that all proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement (whether brought
against a party hereto or its respective affiliates, directors, officers,
shareholders, employees or agents) (each a “Proceeding”)
shall be commenced exclusively in the state and federal courts sitting in the
Atlanta, Georgia. Each party hereto hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the Atlanta, Georgia for
the adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any Proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such Proceeding
is improper. Each party hereto hereby irrevocably waives personal service of
process and consents to process being served in any such Proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to such party at the address in effect for notices to it
under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any manner permitted
by law. Each party hereto hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. If either party shall commence a Proceeding to enforce any
provisions of this Agreement, then the prevailing party in such Proceeding shall
be reimbursed by the other party for its attorney’s fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such
Proceeding.

     

              5.7          Survival.
The representations, warranties, agreements and covenants contained herein shall
survive following the Closing.

     

              5.8          Counterparts;
Execution. This Agreement may be executed in any number of counterparts,
each of which shall be deemed to be an original and all of which together shall
be deemed to be one and the same instrument. In the event that any signature is
delivered by facsimile transmission, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature page
were an original thereof.

     

              5.9          Publicity.
The Purchasers shall not issue any press release or make any public disclosure
regarding the transactions contemplated hereby unless such press release or
public disclosure is approved by the Company in advance. Notwithstanding the
foregoing, each of the parties hereto may, in documents required to be filed by
it with the SEC or other regulatory bodies, make such statements with respect to
the transactions contemplated hereby as each may be advised by counsel is
legally necessary or advisable, and may make such disclosure as it is advised by
its counsel is required by law.

     

              5.10        Severability.
In case any one or more of the provisions of this Agreement shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining
terms and provisions of this Agreement shall not in any way be affected or
impaired thereby and the parties will attempt to agree upon a valid and
enforceable provision which shall be a reasonable substitute thereof, and upon
so agreeing, shall incorporate such substitute provision in this
Agreement.

     

              5.11        Further
Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents, as the other
party may reasonably request in order to carry out the intent and accomplish the
purposes of this Agreement and the consummation of the transactions contemplated
hereby.


    
      
         


      

      
        11

        
          

        

      

      
         


      

    

     

              5.12        Remedies.
In addition to being entitled to exercise all rights provided herein or granted
by law, including recovery of damages, the Purchasers and the Company will be
entitled to specific performance under this Agreement. The parties agree that
monetary damages will not be adequate compensation for any loss incurred by
reason of any breach of obligations described in the foregoing sentence and
hereby agree to waive in any action for specific performance of any such
obligation the defense that a remedy at law would be adequate.

     

    [the
remainder of this page is intentionally blank]


    
      
         


      

      
        12

        
          

        

      

      
         


      

    

     

    
                IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase
Agreement to be duly executed by their respective authorized persons as of the
day and year below.

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    	 
      	 
      	 	 
      	 	 
      
	 
      	
                                            HEALTH
      DISCOVERY CORPORATION

                                          
	 
      	 
      	 	 
      
	 
      	
                                            By:

                                          	 	 
      
	 
      	 
      	 	 
      	 	 
      
	 
      	 
      	 	
                                            Name:

                                          	 	 
      
	 	 	 	 	 
	 
      	 
      	 	
                                            Title:

                                          	 
	 
      	 
      	 	 
      
	 
      	
                                            Date:

                                          	 


                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

       

      IN
MAKING AN INVESTMENT DECISION, THE PURCHASERS MUST RELY ON ITS OWN EXAMINATION
OF THE COMPANY AND THE TERMS OF THE SALE OF THE SHARES AND WARRANT, INCLUDING
THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY
FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE
FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY
OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	 
      	 
      	 	 
      	 
      	 
      	 
      
	 
      	
                                      By:

                                    	 	 
      
	 
      	 
      	 	 
      	 
      
	 
      	 
      	 	
                                      Name:

                                    	 
      
	 
      	 
      	 	 
      	 
      
	 
      	
                                      Date:

                                    	 
	 
      	 
      	 	 
      	 
      
	 
      	
                                      Address:

                                    	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      	 	 
      	 
      
	 
      	
                                      Resident
      of the State of